Objective To study the clinical curative effect of Clomiphene Citrate combined with Marvelon and Spironolactone in the treatment of infertile women with polycystic ovary syndrome. Methods Infertile patients with polycystic ovary syndrome were chosen as the object of study, and they were randomly divided into the treatment group whom were given Clomiphene Citrate, Marvelon and Spironolactone and the control group whom were treated with Clomiphene Citrate, The endocrine indicators and follicle associated index were detected, and the fertilization and endomeirial condition were observed. Results Trt the observation group, testosterone, LH, FSH levels, ovarian volume, number of antral follicles were significantly less than those in the control group (all P＜0.05); the dominant follicle number, endome-trial thickness, appearance quality eggs, successful fertilization, cleavage occurs, and the number of good quality embryos with type A and type B endometrial number of cases were significantly more than the control group (all P ＜ 0.05). Conclusion Clomiphene Citrate combined Marvelon and Spironolactone contributes to improving endocrine disorders and endometrium, and has a positive significance for the treatment of infertility due to polycystic ovary syndrome.%目的 研究克罗米芬联合妈富隆和安体舒通治疗多囊卵巢综合征不孕症的临床疗效.方法 选择多囊卵巢综合征不孕症患者作为研究对象,随机分为给予克罗米芬、妈富隆、安体舒通联合治疗的观察组和克罗米芬治疗的对照组,检测内分泌指标、卵泡相关指标,观察受精情况、子宫内膜情况.结果 观察组睾酮、黄体生成素、卵泡刺激素水平、卵巢体积、窦卵泡数目均明显少于对照组(均P ＜ 0.05);优势卵泡数目、子宫内膜厚度、出现优质卵、成功受精、发生卵裂、优质胚胎例数以及A型和B型子宫内膜例数均明显多于对照组(均P ＜ 0.05).结论 克罗米芬联合妈富隆和安体舒通有助于改善内分泌紊乱和子宫内膜情况,对于多囊卵巢综合征不孕症的治疗具有积极意义.
展开▼
